Gatineau, Canada

Integument-1 study

The study drug consists of a cream of the medication or a placebo (same cream without the active drug) that will be applied once daily for 28 days. This treatment is experimental, and you (or your child) will have 1 in 2 chances to be part of the placebo part of the study. At the end of the study, participants may be eligible to participate in the open-labeled study, which would allow the participants to continue to receive the study treatment. More information will be made available to the participants should they be interested. Blood samples will be collected on screening, day 1 and week 4. If you consent to medical photography, it will be performed at day 1, week 1 and week 4. For more information and to register to the study, please visit the study page: http://eczema-study.com/

We are currently recruiting patients with Palmoplantar Pustulosis (PPP). This study investigates the Efficacy and safety of ANB019.

Visit our website for more information: [_**www.pustulardermstudies.com**_](https://ppp.pustulardermstudies.com/patient/qualify/?media_label=centerwatch)

Analysis of Sensory Profiles and Modulation Mechanisms in People Living with Parkinson's Disease and Comorbid Chronic Pain

We will use thermal, tactile, and pressure standardized stimulators to determine the threshold for painful and non-painful sensations. For people living with PD, we will perform this protocol both in on and off-dopaminergic medication states. Regarding pain modulation, we will study the following mechanisms: a) cognitive modulation: pain expectations will be induced with visual cues to prime participants to anticipate low, moderate, or high pain, and then tested using concordant or discordant heat stimuli; and b) conditioned pain modulation (heterotopic noxious counterirritation analgesia): contact heat pain perception (test stimuli) is tested on one hand before, during and after the immersion of the opposite hand in painfully cold water. Specific pain processing alteration is expected in the form of hypersensitivity for gating nociceptive information and less efficient pain regulation, unique to people living with PD and with greater alteration in people living simultaneously with PD and CP than in those without pain. Understanding the vulnerability to pain in PD and providing comprehensive knowledge on possible underlying mechanisms may help improve patient care and support, and guide future research on the treatment of pain in the disease.

Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease (REASON)

The Canadian Open Parkinson Network

Becoming a C-OPN participant involves completing online questionnaires and 1 in-person visit. There are 3 key components: 1) C-OPN Database * Answer questions about yourself and your lifestyle, medical history, family history, current medications, and other symptoms you may or may not experience. * This can be done either online, or over the phone or in-person with a C-OPN Coordinator. * Information is also gathered from cognitive testing (MoCA) and motor assessment (MDS-UPDRS), both of which are done during the 1 in-person visit with a C-OPN Coordinator at one of the C-OPN Sites listed above. * All information stored in the database is de-identified (meaning removal of any person information). 2) C-OPN Biobank * Participants can choose to donate a blood sample, which would be drawn during the 1 in-person visit with a C-OPN Coordinator at one of the C-OPN Sites listed above. * Blood samples are processed into DNA, serum, and peripheral blood mononuclear cells (PBMC), and stored in Montreal, Quebec. * All blood samples stored in the biobank are de-identified (meaning removal of any person information). 3) C-OPN Registry * Participants can choose to be part of the C-OPN Registry, in which they opt to receive e-mail notifications about upcoming research studies looking to recruit participants. We ask that participants enroll for a period of at least three years so that the C-OPN team can gather information on disease development and progression, as well as natural aging. Follow-up involves completing two questionnaires, either online or over the phone with the Site Coordinator, every 18 months. There is no in-person visit involved in the follow-up.